Paradigm reports “ground-breaking” osteoarthritis discovery: Is it the real deal?

Paradigm Biopharmaceuticals (ASX:PAR) is looking to partner with big pharma.

| More on:
bull vs bear

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price could hit a record high this morning after the medical researcher boasted of a “ground breaking” discovery for its drug designed to treat osteoarthritis in the knees. 

According to the company its patented drug Zilosul has been shown to inhibit ‘nerve growth factor’ (NGF) in bone cells in knee osteoarthritis patients and thus reduce pain. It reports that its research has been peer reviewed and published in the international scientific journal PLoS One.

The research also supports Paradigm’s conclusions from its recent Phase II clinical trial into the treatment of pain and cartilage degeneration in knees and supports its regulatory submissions to the U.S. healthcare regulator the FDA. 

Paradigm will need to run a far larger, more expensive, and clinically comprehensive clinical trial into the drug in order to persuade the FDA of its clinical efficacy. 

The biotech also claimed the drug offered a “very attractive commercial opportunity” for ‘big pharma’ to partner with it in funding research and commercialisation. In part it claimed this is because the drug could help meet the need to treat the “opiate addiction” crisis in the US. 

If it can strike a partnership deal with “big pharma” this is likely to be a major positive for the business and stock. 

All this sounds exciting and Paradigm already has a market value around $488 million despite having no material revenues and expensive drug trials ahead of it. Thankfully it did have around $72 million cash on hand as at June 30, 2019. 

As we’re not far from Melbourne Cup Day, Paradigm could be considered one of the ‘favourites’ amongst a field of speccy ASX biotechs looking for eternal glory.

Others include Mesoblast limited (ASX: MSB), Opthea Limited (ASX: OPH), Next Science Ltd (ASX: NXS) and Bionomics Ltd (ASX: BNO). The first three already posting sales and looking worthy of more research for anyone seeking the next biotech blockbuster. 

However, as a word of warning biotech businesses’ share prices can rise for a long time on the rumour or speculation before tumbling spectacularly on the fact.

Along the way different forces are jockeying for position often in possession of different information to turn profits, with any insider selling or unusual volume something to keenly watch for. 

If you’ve done your research on Paradigm then it might be worth a small punt, although I am not a buyer of shares myself. 

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

a group of people gathered around a laptop computer with various expressions of interest, concern and surpise on their faces. All are wearing spectacles.
Broker Notes

Broker says Life360 (ASX:360) share price has ~80% upside

The Life360 Inc (ASX: 360) share price was one of the best performers on the Australian share market in 2021. …

Read more »

best asx shares represented by best in show ribbon
Broker Notes

3 ‘champion stocks’ for ASX investors in 2022

If you’re a fan of buy and hold investing, then you may want to look at the “champion stocks” listed …

Read more »

Young woman in yellow striped top with laptop raises arm in victory
Share Gainers

These were the best performing ASX 200 shares last week

The S&P/ASX 200 Index (ASX: XJO) had a week to forget after the US Federal Reserve indicated that it would start to …

Read more »

asx share price falling lower represented by investor wearing paper bag on head with sad face
Share Fallers

These were the worst performing ASX 200 shares last week

It was another tough week for the S&P/ASX 200 Index (ASX: XJO) after the US Federal Reserve indicated that it would start …

Read more »

a group of stockbrokers sit in a room with a computer and writing on a wall in chalk indicating calculations and graphs while discussing something on the computer screen.
Broker Notes

Here’s what 67% of brokers think of the current IAG (ASX:IAG) share price

Key points The IAG share price traded up today IAG has made a solid start to the year having rallied …

Read more »

Top 10 - asx shares today
Share Market News

Here are the top 10 ASX shares today

Today, the S&P/ASX 200 Index (ASX: XJO) fought back against the selling pressure throughout the day to finish in the green. …

Read more »

The word inflation written with a ticking time bomb.
Share Market News

Why is it when Jerome Powell sneezes, the ASX 200 catches a cold?

Key points The ASX 200 took a hit following comments from the United States Federal Reserve chair Jerome Powell Expectations …

Read more »

A female financial services professional with a manicured black afro hairstyle turns an ipad screen to show a client across the table a set of ASX shares figures in graph format
Bank Shares

Goldman tips Bank of Queensland (ASX:BOQ) share price to rise 25%

If you’re interested in gaining exposure to the banking sector, then it could be worth considering Bank of Queensland Limited …

Read more »